Aurora Cannabis (ACB)
(Delayed Data from NSDQ)
$7.20 USD
-0.22 (-2.96%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $7.27 +0.07 (0.97%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$7.20 USD
-0.22 (-2.96%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $7.27 +0.07 (0.97%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
How Aurora Cannabis (ACB) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Aurora Cannabis (ACB) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Cannabis ETF Tops in May: 5 Stocks That Led The Way
by Sweta Killa
Inside the best performing stocks in the top cannabis ETF of May.
How Cannabis ETFs Beat S&P 500 Past Month
by Sanghamitra Saha
Cannabis stocks and ETFs jumped last week. Here's why.
Aurora Cannabis Inc. (ACB) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) delivered earnings and revenue surprises of -39.62% and 19.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Aurora Cannabis (ACB) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aurora Cannabis (ACB) stock based on the movements in the options market lately.
Aurora Cannabis (ACB) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Aurora Cannabis' (ACB) fiscal third-quarter results likely to reflect solid prospects in the Canadian market.
What's in Store for Ensign Group's (ENSG) Earnings in Q1?
by Zacks Equity Research
Ensign Group's (ENSG) Q1 results are likely to reflect a better revenue stream.
Are Marijuana Stocks, ETFs Poised for Upbeat Earnings?
by Sanghamitra Saha
"Essential Business" status tagged with marijuana selling amid lockdowns should have helped cannabis stocks and ETFs in the first quarter.
Aurora Cannabis Inc (ACB) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Aurora Cannabis Inc (ACB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Cardinal Health (CAH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Cardinal Health's (CAH) fiscal third-quarter performance is likely to reflect solid performance in Pharmaceutical segment.
3 Medical Product Stocks Set to Beat This Earnings Season
by Trina Mukherjee
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on several factors.
Aurora Cannabis Inc. (ACB) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Aurora Cannabis Inc. (ACB) closed at $0.70, marking a -1.55% move from the previous day.
How Hard Will Coronavirus Hit Zimmer Biomet (Zbh) Q1 Earnings?
by Zacks Equity Research
Zimmer Biomet (ZBH) may have registered improved performances within its Hips and Knees arms due to the nature of the businesses.
What's in the Cards for Quidel (QDEL) This Earnings Season?
by Zacks Equity Research
Quidel (QDEL) is expected to have gained from its Molecular Diagnostic Solutions business in Q1.
Livongo Health (LVGO) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
Livongo Health (LVGO) first-quarter performance to reflect growth in core Livongo for Diabetes solution.
What's in Store for AmerisourceBergen's (ABC) Q2 Earnings?
by Zacks Equity Research
AmerisourceBergen's (ABC) fiscal second-quarter results likely to reflect solid performance at Pharmaceutical Distribution.
What's in Store for Becton, Dickinson's (BDX) Q2 Earnings?
by Zacks Equity Research
Becton, Dickinson's (BDX) fiscal second-quarter results likely to reflect robust performance at BD Life Sciences. However, forex is likely to have remained a woe.
OPKO Health (OPK) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
OPKO Health's (OPK) first-quarter performance is likely to reflect solid performance from Products and RAYALDEE.
Genetic Testing Likely to Drive Invitae's (NVTA) Q1 Earnings
by Zacks Equity Research
Invitae's (NVTA) genetic testing business is expected to have gained from expansion of biopharma partnerships in Q1.
What's in the Cards for DaVita (DVA)This Earnings Season?
by Zacks Equity Research
DaVita (DVA) is expected to have gained from Kidney Care segment in Q1.
What's in Store for Varian Medical (VAR) in Q2 Earnings?
by Zacks Equity Research
Varian's (VAR) solid Oncology platform is expected to have driven fiscal second-quarter performance.
PerkinElmer (PKI) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
PerkinElmer's (PKI) first-quarter results likely to reflect top-line growth and robust performance at Diagnostics segment. However, forex is likely to have remained a woe.
T2 Biosystems (TTOO) to Report Q1 Earnings: What's in Store?
by Zacks Equity Research
T2 Biosystems' (TTOO) first-quarter performance is likely to reflect growth in product revenues.
Aurora Cannabis Inc. (ACB) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
Aurora Cannabis Inc. (ACB) closed the most recent trading day at $0.75, moving -1.68% from the previous trading session.
DENTSPLY SIRONA (XRAY) to Post Q1 Earnings: What's in Store?
by Zacks Equity Research
DENTSPLY SIRONA (XRAY) first-quarter performance to reflect focus on product innovation and R&D.